知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

136 条记录 (耗时 0.024 秒)

    Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
    43.
    发明授权
    Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments 有权
    用共轭抗体或抗体片段治疗人类免疫缺陷病毒感染的方法和组合物

    公开(公告)号：US08333971B2

    公开(公告)日：2012-12-18

    申请号：US11745692

    申请日：2007-05-08

    申请人： David M. Goldenberg ,  Chien Hsing Chang ,  Edmund A. Rossi ,  William J. McBride

    发明人： David M. Goldenberg ,  Chien Hsing Chang ,  Edmund A. Rossi ,  William J. McBride

    IPC分类号： A61K39/00 ,  A61K39/395

    CPC分类号： A61K39/39583 ,  A61K31/4745 ,  A61K31/513 ,  A61K39/42 ,  A61K47/6809 ,  A61K47/6841 ,  A61K47/6879 ,  A61K2039/505 ,  C07K16/1045 ,  C07K16/1063 ,  C07K2317/732 ,  C07K2317/76

    摘要： The present invention concerns methods and compositions for treatment of HIV infection in a subject. The compositions may comprise a targeting molecule against an HIV antigen, such as an anti-HIV antibody or antibody fragment. The anti-HIV antibody or fragment may be conjugated to a variety of cytotoxic agents, such as doxorubicin. In a preferred embodiment, the antibody or fragment is P4/D10. Other embodiments may concern methods of imaging, detection or diagnosis of HIV infection in a subject using an anti-HIV antibody or fragment conjugated to a diagnostic agent. In alternative embodiments, a bispecific antibody with at least one binding site for an HIV antigen and at least one binding site for a carrier molecule may be administered, optionally followed by a clearing agent, followed by administration of a carrier molecule conjugated to a therapeutic agent.

    摘要翻译： 本发明涉及用于治疗受试者的HIV感染的方法和组合物。 组合物可以包含针对HIV抗原的靶向分子，例如抗HIV抗体或抗体片段。 抗HIV抗体或片段可以与多种细胞毒剂如多柔比星缀合。 在优选的实施方案中，抗体或片段是P4 / D10。 其他实施方案可涉及使用抗HIV抗体或缀合至诊断剂的片段在受试者中成像，检测或诊断HIV感染的方法。 在替代实施方案中，可以施用具有HIV抗原的至少一个结合位点和载体分子的至少一个结合位点的双特异性抗体，任选地随后是清除剂，然后施用与治疗剂缀合的载体分子 。

    Phosphorylcholine conjugates and corresponding antibodies
    45.
    发明授权
    Phosphorylcholine conjugates and corresponding antibodies 有权
    磷酰胆碱缀合物和相应的抗体

    公开(公告)号：US08012483B2

    公开(公告)日：2011-09-06

    申请号：US10599934

    申请日：2005-04-15

    申请人： Ulf De Faire ,  Johan Frostegård

    发明人： Ulf De Faire ,  Johan Frostegård

    IPC分类号： A61K39/395

    CPC分类号： G01N33/6854 ,  A61K39/39583 ,  A61K47/646 ,  C07K16/18 ,  C07K16/44 ,  C07K2317/52 ,  G01N33/6893 ,  G01N2800/323 ,  G01N2800/50 ,  G01N2800/52

    摘要： IgG and IgM autoantibody levels against phosphorylcholine in subjects with hypertension (diastolic pressure >95 mmHg) were determined at baseline in order to determine the importance of antibodies for the development of atherosclerosis. The results show that increases in intima-media thickness (IMT) at a follow-up four years after baseline were significantly less prevalent in subjects having high autoantibodies particularly high IgM autoantibodies, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM autoantibodies, against phosphorylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH-phosphorylcholine conjugate. A pharmaceutical composition comprising a phosphorylcholine conjugate (active immunization) or an antibody preparation, for example a monoclonal antibody, with specificity to a phosphorylcholine conjugate (passive immunization) is proposed and the use of these compositions as active or passive immunogens is the treatment or prevention of atherosclerosis.

    摘要翻译： 在基线时测定针对高血压（舒张压> 95mmHg）的受试者中的磷酸胆碱的IgG和IgM自身抗体水平，以确定抗体对动脉粥样硬化发展的重要性。 结果表明，在基线后四年随访的内膜中层厚度（IMT）的增加在具有高自身抗体特别高IgM自身抗体的受试者中明显低于磷酸胆碱。 因此，针对磷酸胆碱的自身抗体，特别是IgM自身抗体的存在或不存在与发生缺血性心血管疾病的风险增加或降低有关。 本发明提出了一种在磷酸胆碱上测定抗体，特别是IgM抗体的方法，以鉴定发生缺血性心血管疾病风险的受试者。 动物实验表明，使用匙孔血蓝蛋白（KLH-磷酸胆碱缀合物）进行主动免疫后，可以在血浆中检测到中等至高水平的抗体，特别是IgM抗体。包含磷酸胆碱偶联物（主动免疫）或抗体制剂的药物组合物， 提出了对磷酸胆碱缀合物（被动免疫）具有特异性的单克隆抗体，并且这些组合物作为活性或被动免疫原的使用是治疗或预防动脉粥样硬化。

    METHOD OF TREATING A PATHOLOGICAL SYNDROME AND A PHARMACEUTICAL AGENT
    46.
    发明申请
    METHOD OF TREATING A PATHOLOGICAL SYNDROME AND A PHARMACEUTICAL AGENT 有权
    治疗病理学综合征和药物代谢的方法

    公开(公告)号：US20100203059A1

    公开(公告)日：2010-08-12

    申请号：US12765385

    申请日：2010-04-22

    申请人： Oleg Iliich Epshtein

    发明人： Oleg Iliich Epshtein

    IPC分类号： A61K39/395 ,  A61P31/12

    CPC分类号： C07K16/44 ,  A61K31/277 ,  A61K39/39583 ,  A61K41/0004 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/00 ,  C07K16/22 ,  C07K16/24 ,  C07K16/241 ,  C07K16/243 ,  C07K16/245 ,  C07K16/246 ,  C07K16/248 ,  C07K16/249 ,  C07K16/26 ,  C07K16/28 ,  C07K16/2806 ,  C07K16/40 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/77

    摘要： A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome.Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.

    摘要翻译： 治疗病理综合征的方法包括向抗原施用超低剂量抗体的活化形式，其中所述活化形式通过反复连续稀释与外部冲击结合获得，并且所述抗原是施用的物质或药剂 影响这种特殊病理综合征的形成机制。 用于治疗病理综合征的药物包含针对抗原的超低剂量的单克隆抗体，多克隆抗体或天然抗体的活化形式，其中所述活化形式通过重复连续稀释和外部治疗（主要基于顺势疗法技术）制备，所述 抗原是作为病理综合征的直接原因或参与调节其形成机制的物质或药物。 在此情况下，针对自身抗原，胎儿抗原，针对外源性或内源性抗原产生超低剂量抗体的活化形式; 也使用抗独特型抗体。